Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. (31st August 2019)

• Record Type: Journal Article
• Authors: Shao, Yu‐Yun; Liu, Tsung‐Hao; Hsu, Chiun; Lu, Li‐Chun; Shen, Yin‐Chung; Lin, Zhong‐Zhe; Cheng, Ann‐Lii; Hsu, Chih‐Hung
• Is Part Of: Liver international. Volume 39:Number 11(2019)
• Page Start: 2184
• Page End: 2189
• Publication Date: 2019-08-31
• Subjects: advanced hepatocellular carcinoma -- alpha-fetoprotein -- alpha‐foetoprotein -- biomarker -- immune checkpoint inhibitors -- immunotherapy; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.14210
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background: Post‐treatment decline in serum alpha‐foetoprotein (AFP) levels has been shown to predict the treatment efficacy of antiangiogenic therapy for advanced hepatocellular carcinoma (HCC). We explored whether a decline in AFP levels was also associated with treatment outcomes of immune checkpoint inhibitors (ICIs) in patients with advanced HCC. Methods: We reviewed all patients who received ICI therapy for advanced HCC. AFP response was evaluated in patients with the pretreatment AFP level of >20 ng/mL. We defined early AFP response as a >20% decline in serum AFP levels within the first 4 weeks of treatment initiation relative to pretreatment levels. We then studied whether early AFP response was associated with treatment outcomes. Results: Sixty patients were enrolled in this study; 43 of them were evaluable for early AFP response. The objective response rate of early AFP responders was significantly higher than that of early AFP nonresponders (73% vs. 14%, P < .001). Early AFP responders, compared with early AFP nonresponders, exhibited significantly longer overall survival (OS) (median, 28.0 vs 11.2 months, P = .048) and progression‐free survival (PFS) (median, 15.2 vs 2.7 months, P = .002). After adjusting for other clinicopathological variables and treatments, early AFP response remained an independent predictor for longer OS (hazard ratio [HR] = 0.089, 95% confidence interval [CI] = 0.018‐0.441; P = .003) and PFS (HR = 0.128, 95% CI = 0.041‐0.399; P < .001). Conclusion: Early AFP response was associated with higher treatment efficacy of ICIs for advanced HCC. Additional validation studies are nonetheless warranted.